

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

APC/Fire(TM) 750 anti-human CD4

RRID:AB_2629693

Type: Antibody

Proper Citation

BioLegend Cat# 300560, RRID:AB_2629693

Antibody Information

URL: http://antibodyregistry.org/AB_2629693

Proper Citation: BioLegend Cat# 300560, RRID:AB_2629693

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Fire(TM) 750 anti-human CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone RPA-T4

Antibody ID: AB_2629693

Vendor: BioLegend

Catalog Number: 300560

Alternative Catalog Numbers: 300559

Record Creation Time: 20250819T233704+0000

Record Last Update: 20250820T055322+0000

Ratings and Alerts

No rating or validation information has been found for APC/Fire(TM) 750 anti-human CD4.

No alerts have been found for APC/Fire(TM) 750 anti-human CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. The Journal of pharmacology and experimental therapeutics, 392(8), 103634.

Hegelmaier T, et al. (2025) Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis. Med (New York, N.Y.), 6(9), 100776.

Petrov L, et al. (2025) Rewired type I IFN signaling is linked to age-dependent differences in COVID-19. Cell reports. Medicine, 6(8), 102285.

Vanshylla K, et al. (2022) Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell host & microbe, 30(1), 69.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 185(3), 493.